<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00020865</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068726</org_study_id>
    <secondary_id>UCLA-0006093</secondary_id>
    <secondary_id>MCNEIL-CAPSS-118</secondary_id>
    <secondary_id>NCI-G01-1965</secondary_id>
    <nct_id>NCT00020865</nct_id>
  </id_info>
  <brief_title>Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia</brief_title>
  <official_title>Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Levofloxacin may be effective in reducing fever and controlling other symptoms of&#xD;
      neutropenia in patients who are being treated for cancer. It is not yet known whether&#xD;
      levofloxacin is more effective than cefepime in reducing fever and controlling symptoms of&#xD;
      neutropenia.&#xD;
&#xD;
      PURPOSE: Randomized phase III trial to compare the effectiveness of levofloxacin with that of&#xD;
      cefepime in reducing fever and controlling symptoms of neutropenia in patients who are being&#xD;
      treated for cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Compare the safety and efficacy of levofloxacin versus cefepime in cancer&#xD;
      patients with fever and neutropenia. II. Compare the percentage of patients whose fever&#xD;
      defervesces and who have no signs or symptoms of infection with and without therapeutic&#xD;
      modification. III. Compare the percentage of survival of patients treated with these 2&#xD;
      regimens with no therapeutic modifications. IV. Compare the overall survival of patients&#xD;
      treated with these 2 regimens regardless of therapeutic modifications. V. Compare the time to&#xD;
      resolution of fever in patients treated with these regimens. VI. Compare the microbiologic&#xD;
      response by pathogen and site of infection in patients treated with these regimens. VII.&#xD;
      Compare the percentage of patients whose fever defervesces only after resolution of&#xD;
      neutropenia (absolute neutrophil count at least 500/mm3) with no therapeutic modification.&#xD;
&#xD;
      OUTLINE: This is a randomized, double-blind, multicenter study. Patients are stratified&#xD;
      according to type of malignancy (solid tumor, including lymphoma vs leukemia), prior&#xD;
      prophylactic antibiotics (yes vs no), and participating center. Patients are randomized to&#xD;
      one of two treatment arms. Arm I: Patients receive levofloxacin IV over 90 minutes once daily&#xD;
      for 14-28 days. Arm II: Patients receive cefepime IV over 30 minutes every 8 hours for 14-28&#xD;
      days. Patients may receive additional antifungal, antibacterial, or antiviral therapy if&#xD;
      condition has deteriorated, no response is seen in 72 hours, or and infection is suspected or&#xD;
      documented. Patients are followed at 1-3 and 7-12 days and then at 3-4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 260-400 patients (130-200 per treatment arm) will be accrued&#xD;
      for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2001</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Supportive Care</primary_purpose>
  </study_design_info>
  <condition>Fever, Sweats, and Hot Flashes</condition>
  <condition>Infection</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Neutropenia</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cefepime hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>levofloxacin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Diagnosis of malignancy Solid tumor (including lymphoma) or&#xD;
        leukemia Hospitalized and anticipated to remain hospitalized during study Febrile defined&#xD;
        as oral temperature of at least 100.4 degrees F (38 degrees C) on 2 occasions within 24&#xD;
        hours OR at least 100.8 degrees F (38.2 degrees C) on a single reading No obvious&#xD;
        noninfectious cause of fever (e.g., platelet transfusion) Neutropenic, defined as absolute&#xD;
        neutrophil count (ANC) currently less than 500/mm3 OR anticipated to be less than 500/mm3&#xD;
        within 24 hours of study entry Anticipated ANC to be less than 500/mm3 for at least 72&#xD;
        hours No neutropenia unassociated with malignancy No chronic neutropenia No neutropenia&#xD;
        anticipated to last more than 14 days No acute myelogenous leukemia unless receiving&#xD;
        consolidation chemotherapy or induction dose that does not prolong neutropenia for more&#xD;
        than 3 weeks No infection due to an identified organism No high likelihood of infection due&#xD;
        to anaerobic organisms, including intra-abdominal infections or perirectal abscess at&#xD;
        admission No known osteomyelitis No requirement for new antifungal agent&#xD;
&#xD;
        PATIENT CHARACTERISTICS: Age: 18 and over Performance status: Not specified Life&#xD;
        expectancy: At least 14 days Hematopoietic: See Disease Characteristics Hepatic: Not&#xD;
        specified Renal: Creatinine clearance at least 20 mL/min No oliguria (urine output less&#xD;
        than 20 mL/hour) unresponsive to fluid challenge Cardiovascular: No shock or hypotension&#xD;
        (supine systolic blood pressure less than 80 mmHg) unresponsive to fluid challenge Other:&#xD;
        Not pregnant or nursing Negative pregnancy test Fertile patients must use effective&#xD;
        contraception No HIV infection with CD4 counts less than 200/mm3 No significant risk for&#xD;
        seizures No unstable psychiatric disorder Weight greater than 40 kg No prior allergic or&#xD;
        severe adverse reaction to study drugs or to any member of the quinolone or beta-lactam&#xD;
        class of antibacterials No disorder or disease that would preclude study&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY: Biologic therapy: No prior sargramostim (GM-CSF) or filgrastim&#xD;
        (G-CSF) for current course of chemotherapy Concurrent GM-CSF or G-CSF allowed if&#xD;
        neutropenia lasts at least 3 days Chemotherapy: See Disease Characteristics Endocrine&#xD;
        therapy: Not specified Radiotherapy: Not specified Surgery: Not specified Other: No prior&#xD;
        treatment under this protocol No prior prophylactic anti-infectives other than acyclovir or&#xD;
        sulfamethoxazole with trimethoprim At least 72 hours since prior systemic antibiotics&#xD;
        (except prophylactic sulfamethoxazole with trimethoprim) At least 30 days since prior&#xD;
        experimental drug or medical device (except drugs currently marketed in the United States&#xD;
        for the treatment of the malignancy) No other concurrent systemic antibacterial agents No&#xD;
        concurrent topical antimicrobial agents&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary C. Territo, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2007</verification_date>
  <study_first_submitted>July 11, 2001</study_first_submitted>
  <study_first_submitted_qc>March 16, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 17, 2004</study_first_posted>
  <last_update_submitted>December 18, 2013</last_update_submitted>
  <last_update_submitted_qc>December 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2013</last_update_posted>
  <keyword>stage I adult Hodgkin lymphoma</keyword>
  <keyword>stage II adult Hodgkin lymphoma</keyword>
  <keyword>stage III adult Hodgkin lymphoma</keyword>
  <keyword>stage IV adult Hodgkin lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>stage I cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage II cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage III cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage IV cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
  <keyword>stage 0 chronic lymphocytic leukemia</keyword>
  <keyword>stage I chronic lymphocytic leukemia</keyword>
  <keyword>stage II chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>blastic phase chronic myelogenous leukemia</keyword>
  <keyword>meningeal chronic myelogenous leukemia</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>fever, sweats, and hot flashes</keyword>
  <keyword>progressive hairy cell leukemia, initial treatment</keyword>
  <keyword>refractory hairy cell leukemia</keyword>
  <keyword>stage I grade 1 follicular lymphoma</keyword>
  <keyword>stage I grade 2 follicular lymphoma</keyword>
  <keyword>stage I grade 3 follicular lymphoma</keyword>
  <keyword>stage I adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage I adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage I adult diffuse large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>T-cell large granular lymphocyte leukemia</keyword>
  <keyword>acute undifferentiated leukemia</keyword>
  <keyword>stage III grade 1 follicular lymphoma</keyword>
  <keyword>stage III grade 2 follicular lymphoma</keyword>
  <keyword>stage III grade 3 follicular lymphoma</keyword>
  <keyword>stage III adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage III adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage III adult diffuse large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV grade 1 follicular lymphoma</keyword>
  <keyword>stage IV grade 2 follicular lymphoma</keyword>
  <keyword>stage IV grade 3 follicular lymphoma</keyword>
  <keyword>stage IV adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
  <keyword>stage IV adult diffuse large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage I adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage II adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage III adult T-cell leukemia/lymphoma</keyword>
  <keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
  <keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>primary central nervous system non-Hodgkin lymphoma</keyword>
  <keyword>neutropenia</keyword>
  <keyword>infection</keyword>
  <keyword>prolymphocytic leukemia</keyword>
  <keyword>AIDS-related peripheral/systemic lymphoma</keyword>
  <keyword>AIDS-related primary CNS lymphoma</keyword>
  <keyword>intraocular lymphoma</keyword>
  <keyword>stage I mantle cell lymphoma</keyword>
  <keyword>contiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>contiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>contiguous stage II mantle cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>contiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>contiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>contiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>contiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>noncontiguous stage II mantle cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III mantle cell lymphoma</keyword>
  <keyword>stage IV mantle cell lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>angioimmunoblastic T-cell lymphoma</keyword>
  <keyword>anaplastic large cell lymphoma</keyword>
  <keyword>stage I mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage II mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage III mycosis fungoides/Sezary syndrome</keyword>
  <keyword>stage IV mycosis fungoides/Sezary syndrome</keyword>
  <keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
  <keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>noncontiguous stage II marginal zone lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>stage I marginal zone lymphoma</keyword>
  <keyword>stage I small lymphocytic lymphoma</keyword>
  <keyword>stage III small lymphocytic lymphoma</keyword>
  <keyword>stage III marginal zone lymphoma</keyword>
  <keyword>stage IV small lymphocytic lymphoma</keyword>
  <keyword>stage IV marginal zone lymphoma</keyword>
  <keyword>contiguous stage II marginal zone lymphoma</keyword>
  <keyword>contiguous stage II small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Fever</mesh_term>
    <mesh_term>Hot Flashes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
    <mesh_term>Cefepime</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

